Summary
Pfizer Inc.'s 2015 10-K filing highlights a pivotal year marked by significant strategic maneuvers, most notably the announcement of a pending merger with Allergan. This transformative deal, valued at approximately $160 billion, aims to combine the two pharmaceutical giants, with Pfizer becoming a subsidiary of the Irish-domiciled Allergan, to be renamed Pfizer plc. The transaction, expected to close in the latter half of 2016, is subject to regulatory and shareholder approvals and represents a major strategic shift for Pfizer. In addition to the Allergan merger, Pfizer completed the acquisition of Hospira for $16.1 billion in cash. Hospira's integration is expected to bolster Pfizer's sterile injectable drugs, infusion technologies, and biosimilars offerings. These significant M&A activities underscore Pfizer's aggressive strategy to reshape its business portfolio and drive future growth. The company also continues to operate under a dual business structure: Innovative Products and Established Products, with ongoing R&D investments focused on key therapeutic areas and biosimilars. Investors should note the company's reliance on key in-line products, with seven biopharmaceutical products and one alliance revenue stream accounting for 44% of total 2015 revenues, making them crucial to financial performance.
Financial Highlights
56 data points| Revenue | $48.85B |
| Cost of Revenue | $9.65B |
| Gross Profit | $39.20B |
| SG&A Expenses | $14.81B |
| Operating Income | $6.95B |
| Interest Expense | $1.20B |
| Net Income | $6.96B |
| EPS (Basic) | $1.13 |
| EPS (Diluted) | $1.11 |
| Shares Outstanding (Basic) | 6.18B |
| Shares Outstanding (Diluted) | 6.26B |
Key Highlights
- 1Announced a significant merger agreement with Allergan valued at approximately $160 billion, expected to close in the second half of 2016, involving a stock transaction and potential cash component.
- 2Completed the acquisition of Hospira for $16.1 billion in cash, expanding its sterile injectables, infusion technologies, and biosimilars capabilities.
- 3The company operates through two main business segments: Innovative Products and Established Products, with distinct strategies for each.
- 4Pfizer's Research and Development efforts are focused on six high-priority areas including oncology, immunology, cardiovascular, vaccines, neuroscience, and rare diseases, along with a growing focus on biosimilars.
- 5Revenues from international operations represented 56% of total revenues in 2015, indicating a strong global presence.
- 6Seven key biopharmaceutical products and alliance revenues accounted for 44% of total 2015 revenues, highlighting their critical importance to financial performance.
- 7The company is actively engaged in share repurchases, with a remaining authorization of approximately $16.4 billion as of December 31, 2015, following an accelerated share repurchase agreement and other repurchases.